Bogle Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bogle Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-96,052	Closed	-$16.4M	–	386
2018 Q3	$16.4M	Buy	96,052 +14,581	+18%	+$2.2M	1.18%	11
2018 Q2	$10.5M	Buy	81,471 +62,031	+319%	+$6.92M	0.76%	66
2018 Q1	$2M	Buy	+19,440	New	+$1.92M	0.15%	150
2014 Q3	–	Sell	-59,130	Closed	-$2.3M	–	374
2014 Q2	$2.3M	Sell	59,130 -111,936	-65%	-$4.54M	0.15%	170
2014 Q1	$7.18M	Buy	+171,066	New	+$7.13M	0.49%	78
2013 Q4	–	Sell	-207,571	Closed	-$5.6M	–	334
2013 Q3	$5.6M	Buy	207,571 +136,669	+193%	+$3.85M	0.57%	66
2013 Q2	$1.65M	Buy	+70,902	New	+$1.28M	0.2%	157

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Bogle Investment Management's LGND Position: Q4 2018 in Review

Bogle Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 96,052 shares — an estimated $16.4M sold.

Bogle Investment Management first reported a position in LGND in Q2 2013 and held it in 7 quarters. The position peaked at $16.4M in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Bogle Investment Management reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Bogle Investment Management sold 96,052 Ligand Pharmaceuticals shares in Q4 2018, an estimated $16.4M.
Bogle Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Bogle Investment Management's Ligand Pharmaceuticals position peaked at $16.4M in Q3 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Bogle Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.